Recently, however, the effectiveness of GIP as a diabetic therapeutic agent has been reappraised based on a growing body of new evidence indicating that promoting GIP action/activity, either alone or in combination with GLP-1 analogues, is beneficial for treating T2D [53,57]. Here, GLP1R is linked to type 2 diabetes mellitus.